T-DM1-related telangiectasias: a potential role in secondary bleeding events
V. Sibaud(Institut Claudius Regaud), Jean‐Pierre Delord, Laurence Lamant(Centre National de la Recherche Scientifique), Mario E. Lacouture(Garden City Community College), Florence Dalenc(Institut Claudius Regaud), P. Combemale(Centre Léon Bérard), Émmanuelle Vigarios(Institut Claudius Regaud), Jean‐Louis Lacaze(Institut Claudius Regaud)
Cited by 22
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
|Journal of Thoracic Oncology|2019|437